Absolute Rules for Topical Corticosteroid Withdrawal
The topical corticosteroid withdrawal (TCSW) is defined as an adverse reaction An adverse that arises after stopping the use of a topical steroid. This syndrome can manifest after prolonged, inappropriate, or frequent use of moderate-to-high potency steroid topicals. There are two well-differentiated clinical presentations of topical steroid withdrawal:
- Red, burning skin: This phenomenon has been incorrectly named in various ways, including «topical steroid addiction» or dermatitis steroid dermatitis.
- Photosensitivity Papulopustular eruptions: These include manifestations such as steroid rosacea and perioral or periorificial dermatitis. Perioral o periorificial.
Causes of Skin Redness and Affected Population
Indicators of topical corticosteroid withdrawal can develop develop between days and weeks after discontinuing the high-potency topical corticosteroid that was abused or excessively used, especially if it was used to treat mild to moderate atopic dermatitis. Typically, treatment with the topical steroid has been prolonged (more than 12 months) and frequent, such as daily or even more continuous application. This syndrome has not been documented with the correct and prescribed use of topical steroids.
All clinical cases documented in medical literature regarding this form of steroid withdrawal have involved patients over 18 years of age, with a clear predominance of the female sex.
The predominance The widespread predominance of skin redness following topical steroid withdrawal is still not fully understood. It is unknown whether the apparent lack of pediatric cases is due to lower susceptibility in children or underreporting. In fact, a Japanese study on atopic dermatitis identified that 12% of patients presented with poorly controlled skin disease, a group that would presumably include those with topical steroid dependence. pediatric se debe a una menor susceptibilidad en niños o a una subnotificación. De hecho, un estudio japonés sobre dermatitis atópica identificó que el 12% de los pacientes presentaban una enfermedad cutánea mal controlada, un grupo que presumiblemente incluiría a aquellos con dependencia a esteroides tópicos.
Clinical Features of Topical Corticosteroid Withdrawal
Prior to discontinuing the topical corticosteroid, the affected skin generally looks normal or near-normal, although symptoms such as itching may persist, episodes of angioedema without hives may originate from angiotensin-converting enzyme (ACE) inhibitors., patches of eczema "resistant" eczema, or itchy nodules. nodules with an edema.
The redness (or erythemaerythema) usually starts on the face, genital area, or some other area previously treated with steroids; in some cases, this reaction may spread to sites that never received the medication application.
At the onset of the flare, the skin may feel noticeably thicker. Swelling (edema) and papules are common.edema) and papules.
The symptom The most frequently reported symptom by patients is an intense burning and/or stinging sensation. Likewise, itching may occur, particularly when the redness begins to subside and the dry and peeling (desquamative) phase begins.desquamative). Patients often report extreme skin sensitivity, including intolerance to moisturizers and other external factors.
Excessive sweating and itching sensation. Presentation of wheals wheals in the affected area, followed by a recovery zone.
One of the crucial challenges is discerning whether the observed skin reaction is a product of discontinuing topical corticosteroids or simply an exacerbation of the underlying dermatological pathology for which those steroids were prescribed.
Complications Associated with Topical Corticosteroid Withdrawal
Patients experiencing red and intensely burning skin after stopping the use of topical corticosteroids may suffer significant distress due to the severity of the itching, resulting sleep deprivation, and difficulties in therapeutic management.
Additionally, they may develop a secondary infection.
Diagnosis of Topical Corticosteroid Withdrawal
To define the topical corticosteroid withdrawal syndrome, the following essential characteristics must be present:
- A rash A rash that emerges days or weeks after discontinuing the topical corticosteroid applied continuously for many months. It is common for this flare to exceed in severity the rash that prompted the initial treatment.
- The rash is geographically limited to the area where the topical corticosteroid was applied, at least in the initial phase, although it may subsequently spread more extensively.
Clinically distinguishing this syndrome from a flare of the primary skin condition (such as atopic dermatitis) can be complex. Topical corticosteroid withdrawal should be considered if the following criteria are met:
- The predominant symptom is a burning sensation rather than itching.
- The redness presents as a confluent confluent (joined) area instead of presenting an irregular pattern.
- The skin rash resembles atopic dermatitis but affects unusual locations and feels "different.".
- There is a history of constant and prolonged use (more than one year) of medium or high-potency topical corticosteroids.
A biopsy A skin biopsy is generally not useful for differentiating withdrawal from a flare of the underlying skin disease, because the histopathology of both conditions can overlap. histopathology of both conditions can overlap.
Patch Tests Patch tests can help identify specific cases of contact allergy contact to topical agents applied to the skin, including corticosteroids, other topical medications, moisturizers, or cosmetics.
Treatment Strategies for Topical Corticosteroid Withdrawal
There is no universally accepted therapeutic regimen for topical corticosteroid withdrawal syndrome, other than discontinuing the use of the topical corticosteroid. However, it has not yet been determined whether discontinuation should be gradual (tapered) or immediate (abrupt). Reports from Japan suggest minimal difference in outcome, so immediate cessation is usually recommended. cessation cessation. A gradual course of oral steroids is useful if dependence is suspected to be linked solely to the use of potent topical corticosteroids. In cases of steroid rosacea and periorificial dermatitis, low-dose oral tetracyclines and isotretinoin have been successfully used.
Supportive measures such as applying cold compresses and psychological support are frequently advised. If a secondary infection develops, oral antibiotics may need to be administered for its prevention or treatment.
Prevention of Topical Corticosteroid Withdrawal Syndrome
Prevention is the primary focus: both physicians and patients must be aware of the risk and avoid frequent and prolonged use of moderate-to-high potency topical corticosteroids. The probability of developing withdrawal increases significantly the greater the potency of the product, the period of application (especially if it exceeds one year), and the frequency of application (more than once a day).
However, concerns about the risk of withdrawal should not prevent the appropriate treatment of conditions like atopic dermatitis with topical corticosteroids, given that many more patients respond positively to their correct use than those who ultimately develop a withdrawal rash.
Outlook and Prognosis of Topical Corticosteroid Withdrawal
The duration of the acute phase acute of topical corticosteroid withdrawal and the time to reach maximum symptom intensity vary considerably, ranging from days to months, before the skin finally returns to a "normal" appearance. However, full recovery of the baseline skin condition may take weeks or even years.
